SARS-CoV2 / COVID-19 / Corona
The situation regarding COVID-19, especially on the subject of vaccinations, is still very dynamic. We try to keep ourselves and all information here up to date, but we ask for your understanding that we cannot assume any liability for the following information.
With the senate resolution of March 29, there is an obligation to wear an FFP2 mask without a valve in medical facilities as well as in public transport and shops from March 31, 2020!
All unvaccinated patients we ask for a negative (self-)rapid test for the performance of the consultation!
Our patients include people who cannot be vaccinated for medical reasons. Likewise, people with severe immunodeficiency, for whom sufficient immune protection may not be built up even after additional doses of vaccine. For these groups of people as well as for ourselves, the continued adherence to distance and hygiene rules with legally prescribed use of FFP2 masks in the office rooms is particularly important.
Vaccination in office
We do everything in our capacity and with all our energy to meet the vaccination wishes of all our patients as quickly as possible. However, we are NOT a vaccination centre and can only carry out vaccinations in the office to a limited extent without giving up our function as a GP office and completely neglecting necessary safety precautions. Therefore, please also have understanding for us! We must continue to organise, plan and implement initial, final and booster vaccinations in addition to the currently required flu vaccinations. We have to carry out the vaccinations in addition to the normal practice routine, so we ask for your understanding that we are not able to carry out detailed explanatory talks at the vaccination appointment. Please clarify any questions in advance.
We vaccinate in accordance with the current Corona vaccination regulations and the recommendations of the STIKO (Standing Committee on Vaccination). Please note that the vaccine is not supplied to the office in individually applicable single doses, but must be prepared for vaccination in the office. This for mandatory requirements of the vaccination process, as we cannot store the processed vaccine indefinitely!
We no longer keep a waiting list, since a considerable proportion of those waiting did not canceled their appointment after an external vaccination. This means an increase in organisational work for us, which we cannot and do not want to do any more! If you are unable to attend an agreed vaccination appointment, please inform us immediately so that we have a chance to provide a replacement and do not have to dispose any vaccine.
According to the current recommendation, we are currently vaccinating only with a version of the vaccine “Comirnaty” from BioNTech/Pfizer.
We continue to have no complete influence on the delivery quantities and vaccine manufacturers. We can therefore only vaccinate what we receive. If you do not wish to follow our vaccination offer and procedure, please make an appointment for vaccination elsewhere. Our procedure is non-negotiable for the sake of the further day-to-day running of the office as well as for safety!
At the vaccination appointment you must be symptom-free and present a completed information/consent sheet. This can be completed online as a digital questionnaire or is available for download & self-print.
Contraindications to vaccination
There are very few reasons (contraindications) why a person cannot be permanently or temporarily vaccinated against COVID-19. According to the RKI’s assessment, only very few people (individual cases) cannot be vaccinated due to allergies to components of the COVID-19 vaccines. As a rule, people who cannot be vaccinated with one of the vaccine types (mRNA vs. vector-based) can be vaccinated with the other.
Our contraindications are:
- febrile temperatures (> 38.5°C)
- high-dose antibiotic use
or immunosuppressive therapy (e.g. cortisone, MTX, chemotherapy)
False contraindications include:
- Banal infections, even if they are accompanied by subfebrile temperatures (≤ 38.5 °C).
- Cancer, rheumatological diseases
- Allergies (which are not specific to components of the vaccination)
- Treatment with low-dose antibiotics or corticosteroids or locally applied steroid-containing preparations
- Bleeding tendency/administration of anticoagulants
- Pre-existing neurological diseases such as multiple sclerosis
- Chronic diseases such as chronic inflammatory bowel disease or kidney disease.
In case of a positive rapid test, please do not come to the office unannounced but contact us by phone/email or directly to a COVID praxis nearest to you!
Who when what?
Recommendations for basic immunisation (1st and 2nd dose):
Children under 5 years: currently no licensed vaccine and no vaccination recommendation.
Children 5 to 11 years: limited recommendation, reduced dose (0.1ml – 10µg) “Comirnaty” by BioNTech/Pfizer; vaccination interval 3 to 6 weeks
Adolescents 12 to 18 years: normal dose (0.3ml – 30µg) “Comirnaty” from BioNTech/Pfizer or “Spikevax” from Moderna; vaccination interval 3 to 6 weeks
Adults 19 years and older: “Comirnaty” from BioNTech/Pfizer or “Spikevax” from Moderna; vaccination interval 3 to 6 weeks.
Special case “Vaccine Janssen” by Johnson&Johnson: an additional vaccine dose of an mRNA vaccine starting 4 weeks after the Janssen vaccination
The STIKO recommends a second booster (4th vaccination) for all persons over 60 years of age. In addition, people five years of age and older with an increased risk of severe COVID-19 courses due to an underlying disease such as asthma, diabetes or cardiovascular disease, as well as health and care workers, should be vaccinated again.
If there is a special indication for a booster vaccination at the age of 5 to 11 years, the STIKO communication states that the monovalent wild-type vaccines recommended and approved for this age group should continue to be used. The omicron-adapted, bivalent vaccines are only approved for persons aged 12 years and older.
A further booster vaccination is currently not recommended for these groups of people. According to the STIKO, it may make sense to administer a further vaccine dose to particularly vulnerable people such as the very elderly and people with immunodeficiency after the fourth immunological event (vaccination or infection) – usually after six months at the earliest.
never fallen ill: booster 5 to 6 months after last vaccination.
Disease (positive PCR) without COVID-19 vaccination: one booster 6 months (earliest 4 weeks) after cessation of COVID-19 symptoms or diagnosis. Booster 6 months after vaccination.
Disease (positive PCR) after COVID-19 vaccination (regardless of number of vaccine doses): booster 6 months after end of COVID-19 symptoms or diagnosis.
COVID-19 vaccines and modes of action
mRNA vaccine: BioNTech, Moderna, Curevac
Vector vaccine: AstraZeneca, Johnson & Johnson, Sputnik V, CanSino Biologics
Inactivated vaccine: Novavax, Sinopharm, Sinova
Vaccines with vector viruses use harmless viruses as carriers of genetic information of the actual virus. Information about certain proteins is incorporated into the genetic material of these vector viruses (carrier viruses). The aim is to make the immune system form antibodies against these proteins and to trigger other defence reactions. Upon contact with the actual virus, the body is then prepared and can better contain the infection.
Vaccines made from messenger RNA (mRNA) this is a new concept. No weakened virus or individual parts of a virus are used for vaccination. Instead, the vaccine consists only of genetic information in the form of messenger RNA or mRNA. The RNA molecules contain blueprints for proteins that the vaccinated person’s body is supposed to produce itself.
Dead vaccines based on viral protein are classic vaccines (such as tetanus or flu vaccines) that are based on inactivated pathogens.
Protein-based inactivated vaccines are also said to have a good protective effect. Most of the applications for approval have been submitted to the European Medicines Agency (EMA). However, approvals are still pending, which is why availability in Germany cannot be estimated with certainty at the present time.
Vaccine safety & risk of infection
Data from licensing studies as well as from studies in widespread use demonstrate that the COVID-19 vaccines used in Germany prevent SARS-CoV-2 infections to a significant degree. These vaccines have a marketing authorisation and are equivalent in safety, efficacy and quality in terms of basic immunisation and boosting.
Why an increasingly high proportion of vaccinated people among COVID-19 patients in hospital does not mean that vaccination is not working. Why this is so is explained briefly and concisely by the RKI .
As is well known, there are various opinions about the efficiency and necessity of the Corona vaccination. We would like to refer to the information of the Johns Hopkins Medicine on Corona vaccination myths. In this context, we would like to emphasise that we work in the service of our solidarity-based health care system and share its position on vaccination 100%. From people who – for whatever reasons – do not share this position, we also demand the freedom of opinion that we demand for ourselves. Discussions about the existence and categorical necessity of vaccination are not held in the consultation hours! If this is not acceptable, we refer to the free choice of doctor in our health system and wish you all the best!